BioSpace News Archive

Palisade Bio, Inc. (NASDAQ: PALI), a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, announced today that Robert McRae has joined the senior management team as Senior Vice President, Operations and Strategic Development.

NRx Pharmaceuticals (Nasdaq: NRXP), a clinical-stage, biopharmaceutical company, today announced results of a review conducted by the Therapeutics and Prevention Data Safety and Monitoring Board (DSMB) of the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH) on February 14, 2022.

Axon Therapies, a private company focused on addressing a root cause of heart failure, today announced the appointment of Brian Farley to the company’s Board of Directors.

Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), today announced that on Friday, February 11, 2022, the company was informed by the U.S Food and Drug Administration (FDA) via e-mail communication that its Phase 1 clinical trial for LB1901 has been placed on clinical hold.

Cell and gene therapy innovators can now leverage new integrated commercial packaging and distribution services from Thermo Fisher Scientific, designed to seamlessly transition therapies from clinic to commercial launch for patients across the U.S. and Europe.

Colorectal cancer has become a great healthcare burden in Korea. To find out why, scientists at Dongguk University in Korea examined the cancer caseloads against the distribution of dietary and lifestyle factors observed in the population.

Jaguar Health today announced that Napo Therapeutics has been granted Small and Medium Enterprise (SME) designation by the European Medicines Agency (EMA).

XIL Health, today announces its innovative Vaccine Dashboard for U.S.-based retail pharmacies - allowing easy access to tracked information on COVID-19 and all other vaccines given by pharmacies, including pediatric vaccines.

Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced that it will report its full year 2021 financial results on Tuesday, February 22nd.

Statera Biopharma, Inc. (Nasdaq: STAB), announced today that it has received Central Institutional Review Board (IRB) approval to conduct a Phase 3 clinical trial for STAT-201 in the treatment of pediatric Crohn’s Disease (CD), a chronic relapsing inflammatory condition of the gastrointestinal tract.